STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims
Executive Summary
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
You may also be interested in...
US FDA Again Stops At Qualified Health Claim For Supplements: Cranberry Reduces UTI Risk
FDA intends to exercise enforcement discretion regarding QHCs about the association between reduced risk of recurrent UTI and use of supplements with at least 500 mg cranberry fruit powder and of cranberry juice beverages containing at least 27% cranberry juice.
Largest Meta-Analysis Suggests Higher Omega-3 Doses For Heart Health
Omega-3 supplementation results in 8% reduction in heart attack and coronary heart disease risk over a five-year period versus placebo, finds a meta-analysis in JAMA. Encompassing 120,000 patients, research updates recent meta-analyses with addition of three studies in past year, two casting doubt on heart health benefits of omega-3s.
FDA Holds Line On Omega-3 Claims, But Gives Enforcement Discretion For More
Agency says "some credible evidence" suggests intake of EPA and DHA "may reduce the risk of hypertension by lowering blood pressure, this evidence is inconclusive and highly inconsistent" and does not support actual approval of a qualified health claim.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: